National Institute for Health and Clinical Excellence (NICE)
Offer personalised care to support those who need help to live at home
Home care visits to elderly people should last for at least half an hour and focus on what they can or would like to do rather than on what they can’t do, says NICE.
Almost half a million people received home care in England in 2013/14, with 80 per cent of them at least 65 years old.
Demand for home care is expected to grow in the coming years due to England’s ageing population. It is predicted that almost 1 in 4 people in England will be aged 65 and older by 2035. This comes at a time when the social care sector is facing up to a funding crisis.
Aspirational but achievable
NICE’s first guideline for the social care sector sets out recommendations that are aspirational but achievable. Many of the recommends require a change in attitude rather than additional funding. What’s more, a number of local authorities are already getting it right and delivering high-quality services.
The guideline, which is also of relevance to Clinical Commissioning Groups and others who commission home care services, recommends that services support the aspirations, goals and priorities of each person, and that they and their carers are treated with empathy, courtesy and respect.
Home care workers should make sure their support focuses on what people can or would like to do rather than a “one size fits all” service. For example, if a person can still feed themselves then they should be supported to do this rather than being spoon-fed.
NICE recommends that commissioners ensure that home care workers should be given enough time to do their job without being rushed or compromising the dignity of the person who uses services. This includes having enough time to talk to the person and their carer, and adequate travel time between appointments.
Home care visits shorter than half an hour should only be made if the home care worker is known to the person and the visit is part of a wider package of support and the purpose of the visit can be properly undertaken in that time.
Continuity of care
The guideline also highlights the importance of prioritising continuity of care by ensuring the person has the same home care worker or workers so that they can become familiar and build a relationship.
Professor Gillian Leng, deputy chief executive and director for health and social care at NICE, said: “The need for support at home is something that is likely to affect many of us. As we age, most of us will want to continue living in our own homes, surrounded by a lifetime of memories, for as long as we can.
“Helping a person remain as independent as possible is an important component to maintaining their wellbeing. Without good support, older people can suffer from social isolation, malnutrition or neglect. They may also be at risk of injuring themselves, perhaps from a fall or other accident, if they do not receive adequate help and could end up in hospital.”
Bridget Warr, chief executive of the United Kingdom Homecare Association (UKHCA), and chair of the guideline group, said: "The help each person needs will differ and it is important that the homecare delivered is tailored specifically to the individual; his or her needs, wishes and aspirations.
“The guideline emphasises the importance of people receiving support from trained and competent staff with whom they are familiar. For this to happen, those commissioning and delivering home care must work together with the person wanting support to plan the right co-ordinated care in the way the person wants. They should be sure that there is adequate time allowed for the home care worker to provide good, sensitive support in a way that protects and enhances the person's dignity, wellbeing and independence.
“The guideline spells out how this can be achieved and will, I hope, help to provide focus for those many providers and commissioners who want to ensure high quality, responsive, sustainable support at home is available to those who want it."
"I might be the only person they see that day"
Miranda Okon, a home care worker in London who helped to develop the guideline, said: “The role of a home care worker is a valuable one to many older people and their families. I see 3 or 4 people a day and help them with things such as doing their laundry or shopping, cooking meals, or helping them to wash. I also make sure I have time to chat to them as I might be the only person they see that day.
“Visits of less than half an hour are not allowed in the area where I work and this makes sure I am able to do everything I need to for each person without rushing. But this isn’t happening everywhere and if workers are in a situation where they have to choose which task to do before they have to rush out of the door this isn’t acceptable. Home care workers deserve proper recognition and support to do their jobs well and giving them enough time is vital to this.
"Regular training and development is also important: not only will it lead to a more skilled workforce, but may even help to retain staff by giving them a better defined career path.”
Minister for Community and Social Care, Alistair Burt welcomed the guideline. He said: “Most of us envisage spending our old age in our own home and we want to provide the great care that can make that a reality. We asked NICE to develop this guideline so that everyone involved in providing home care has clear standards that we will expect them to follow. This will not only provide reassurance for countless families who rely on this care but for the thousands of workers who want the time and support to be able to give people the care they deserve.”
Have your say on the development of a quality standard for home care that will focus on roughly 6-8 specific key areas of care most in need of improvement.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
NICE announces next steps for publication of its guideline on ME/CFS20/10/2021 14:20:00
NICE has today (20 October 2021) announced the next steps for publication of its updated guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS)
New draft guideline to help reduce health inequalities in people experiencing homelessness07/10/2021 09:15:00
NICE and the Centre for Homelessness Impact (CHI) have jointly published a new draft guideline to increase the access people experiencing homelessness have to health and social care services and improve their health outcomes.
NICE updates managing COVID guideline with new monoclonal antibody recommendations06/10/2021 11:15:00
NICE has updated its managing COVID-19 guideline to include new recommendations on using monoclonal antibodies to treat COVID-19 patients in hospital.
NICE recommends first treatment in two decades for sickle cell disease05/10/2021 11:15:00
Hundreds of people will be eligible for a new treatment for sickle cell disease following draft guidance published today (5 October).
People with advanced or metastatic urothelial cancer to get life-extending treatment01/10/2021 11:15:00
Around 130 people per year with untreated locally advanced or metastatic urothelial cancer will be eligible for a new life-extending treatment after NICE published final draft guidance yesterday (30 September 2021) recommending atezolizumab.
Update on the NICE ME/CFS guideline roundtable discussion22/09/2021 09:10:00
The roundtable meeting to discuss the updated guideline on the diagnosis and management of ME/CFS will be held on October 18th in London. It is being convened after publication of the guideline was paused when issues were raised by some professional groups during the pre-publication period
NICE and PHE recommend all employers give mental health training for managers17/09/2021 11:10:00
All managers should be given the skills to support employees with mental health issues, NICE and PHE have said in new guidance.
NICE recommends treatment for people with juvenile idiopathic arthritis10/09/2021 11:15:00
NICE yesterday (9 September 2021) published final draft guidance which recommends tofacitinib (also known as Xeljanz and made by Pfizer) as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in people 2 years and older.